Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy – (Eye 31, 163 (January 2017))
Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy Eye 31, 163 (January 2017). doi:10.1038/eye.2016.215 Authors: F Ricci, M Parravano, F Regine, M Sciamanna, M Tedeschi, F Missiroli & M Varano
Recent subspecialty trends in ophthalmology consultant appointments – (Eye 31, 164 (January 2017))
Recent subspecialty trends in ophthalmology consultant appointments Eye 31, 164 (January 2017). doi:10.1038/eye.2016.176 Authors: O Bowes, W Dean & A D Borman
Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study – (Eye 31, 166 (January 2017))
Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study Eye 31, 166 (January 2017). doi:10.1038/eye.2016.276 Authors: F G Holz, R Tadayoni, S Beatty, A R Berger, M G Cereda, P Hykin, G Staurenghi, K Wittrup-Jensen, J Nilsson, K Kim & S Sivaprasad
The association of geographic atrophy and decreased renal function in patients with age-related macular degeneration – (Eye 31, 62 (January 2017))
The association of geographic atrophy and decreased renal function in patients with age-related macular degeneration Eye 31, 62 (January 2017). doi:10.1038/eye.2016.261 Authors: H B Leisy, A Rastogi, G Guevara, M Ahmad & R T Smith
The zebrafish eye—a paradigm for investigating human ocular genetics – (Eye 31, 68 (January 2017))
The zebrafish eye—a paradigm for investigating human ocular genetics Eye 31, 68 (January 2017). doi:10.1038/eye.2016.198 Authors: R Richardson, D Tracey-White, A Webster & M Moosajee